March 2026
The global cancer biologics market size was valued at USD 117.45 billion in 2025 and is expected to hit around USD 235.81 billion by 2035 with a CAGR of 7.22%.
September 2026
The global non-invasive cancer diagnostics market size is projected to hit around USD 350.78 billion by 2035 from USD 185.94 billion in 2026, with a CAGR of 7.32%.
September 2026
The cancer immunotherapy market size is calculated at USD 151.26 billion in 2026 and is projected to hit around USD 367.63 billion by 2035, at a CAGR of 10.42%.
September 2026
The oncology/cancer drugs market size is calculated at USD 214.70 billion in 2026 and is projected to hit around USD 554.69 billion by 2035 with a CAGR of 11.17%.
September 2026
The global fallopian tube cancer therapeutics market size is expected to increase from USD 2.14 billion in 2026 to hit around USD 5.41 billion by 2035, growing at a CAGR of 10.86%.
September 2026
The global colorectal cancer therapeutics market size is expected to hit around USD 19.95 billion by 2034 from USD 12.79 billion in 2024 with a CAGR of 4.55%.
September 2026
The global blood cancer diagnostics market size is estimated to hit around USD 22.55 billion by 2035 increasing from USD 12.46 billion in 2026, with a CAGR of 6.83%.
September 2026
The global cancer immunotherapy drug discovery outsourcing market size is expected to hit around USD 4.19 billion by 2035 from USD 1.83 billion in 2026, with a CAGR of 9.70%.
September 2026
The global prostate cancer diagnostics market size is expected to hit around USD 18 billion by 2035 from USD 10.34 billion in 2026 , with a CAGR of 6.36%.
September 2026
The global biologics and biosimilars market size is estimated to hit around USD 2,426.85 billion by 2035 increasing from USD 700.76 billion in 2026, with a CAGR of 14.80%.
September 2026
The global cancer diagnostics market size was exhibited at USD 184.96 billion in 2026 and is predicted to surpass around USD 378.44 billion by 2035 with a CAGR of 8.33%.
September 2026
The in-vitro colorectal cancer screening tests market size is projected to surge around USD 1,310 million by 2034 from USD 1030 million in 2026, with a CAGR of 3.05%.
September 2026
The global breast cancer market size was estimated at USD 27.37 billion in 2026 and is projected to hit around USD 40.11 billion by 2035 with a CAGR of 4.34%.
September 2026
The global Cancer IVD market size was estimated at USD 21.87 billion in 2026 and is projected to hit around USD 34.97 billion by 2034 with a notable CAGR of 6.04%.
September 2026
The global breast cancer therapeutics market size was valued at USD 35.91 billion in 2026 and is expected to hit around USD 66.72 billion by 2035, at a CAGR of 7.27%.
September 2026
The global biologics CDMO market size was valued at USD 25.08 billion in 2026 and is projected to hit around USD 55.11 billion by 2035 with a healthy CAGR of 9.14%.
September 2026
The global esophageal cancer market size is estimated to hit around USD 36.51 billion by 2035 increasing from USD 18.03 billion in 2026, with a CAGR of 8.17%.
September 2026
The global next-generation biologics market size was evaluated at USD 135.12 billion in 2026 and is predicted to hit around USD 301.22 billion by 2034, growing at a CAGR of 10.54% from 2025 to 2034.
September 2026
The ovarian cancer drugs market reached USD 4.36 billion in 2026, with prominent companies such as AstraZeneca plc (UK), F. Hoffmann-La Roche Ltd. (Switzerland), GlaxoSmithKline plc (GSK) (UK), AbbVie Inc. (USA), Merck & Co., Inc. (USA) leading the ovarian cancer drugs market.
September 2026
The CAR-T therapies for blood cancers market generated USD 8.09 billion in 2026, with prominent CAR-T therapies for blood cancers market companies including Novartis AG, Gilead Sciences, Inc. (Kite Pharma), Bristol Myers Squibb Company (Celgene/Juno Therapeutics), Johnson & Johnson (Legend Biotech Corporation).
September 2026
The U.S. biologics market was worth USD 223.60 billion in 2026, with key U.S. biologics market players including Eli Lilly & Company, Samsung Biologics, F Hoffman La Roche.
September 2026
The AI in cancer immunotherapy drugs market reached USD 3.52 billion in 2026, featuring leading AI in cancer immunotherapy drugs market companies such as Exscientia, Insilico Medicine.
September 2026
The wound care biologics market size is expected to surpass around USD 11.22 billion by 2034, increasing from USD 6.65 billion in 2026, with a CAGR of 6.75%
September 2026
The global cancer stem cells market size is anticipated to worth around USD 6.60 billion by 2034 from USD 2.69 billion in 2026 with a CAGR of 11.92%.
September 2026
The lung cancer therapeutics market size totalled USD 38.23 billion in 2026, with major lung cancer therapeutics market players including AstraZeneca, BoehringerIngelheim, Bristol-Myers Squibb Company, Eli Lilly and Company, Hoffmann-La Roche, Merck & Co, Pfizer Inc.
September 2026
The cancer therapeutics and biotherapeutics market size reached USD 228.73 billion in 2026, with leading cancer therapeutics and biotherapeutics market companies including Amgen Inc., Bristol-Myers Squibb, Celgene Corporation.
August 2026
The global cancer biomarkers market size was estimated at USD 15.58 billion in 2025 and is projected to hit around USD 47.14 billion by 2035 with a CAGR of 11.71%.
August 2026
The global cancer therapeutics market size was evaluated at USD 212.58 billion in 2025 and is expected to surpass around USD 501.07 billion by 2034 with a CAGR of 8.95%.
August 2026
The global biologics market was valued at USD 487 billion in 2025 and is expected to hit around USD 1243.80 billion by 2035, growing at a CAGR of 9.83%.
August 2026
The global cancer registry software market size is expected to increase from USD 94.68 million in 2025 to hit around USD 301.40 million by 2035, with a CAGR of 12.28%.
+1 650 460 3308
+61 485 981 310 +91 87933 22019
sales@precedenceresearch.com